Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer, a life sciences company listed on Nasdaq as SEER, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded presentation will be available online starting November 22, 2021. Additionally, Seer will conduct investor meetings on December 1 and 2, 2021. The company is focused on its Proteograph Product Suite, designed for efficient and deep proteomic analysis, accessible to many laboratories. The suite is for research use only and not intended for diagnostic procedures.
Seer, Inc. reported third-quarter 2021 revenues of $2.2 million, a significant increase from $72,000 in Q3 2020, driven by the Proteograph Product Suite. Product-related revenue reached $1.6 million, with a gross profit of $1.2 million and a gross margin of 54%. However, the company's operating expenses surged to $19.6 million, resulting in a net loss of $18.4 million. As of September 30, 2021, Seer held approximately $506.6 million in cash and investments. The company is on track for a Broad Release of its product in early 2022.
Seer, Inc. (Nasdaq: SEER) has appointed Rachel Haurwitz, Ph.D., CEO of Caribou Biosciences, to its Board of Directors effective November 8, 2021. Haurwitz's extensive experience in genome editing is expected to bolster Seer's mission in proteomics. David Singer will step down from the board, marking a significant leadership transition. The addition of Haurwitz, a recognized figure in the biotechnology field, reflects Seer’s commitment to advancing its innovative Proteograph technology aimed at enhancing biological insights.
Seer, Inc. (Nasdaq: SEER) will announce its Q3 2021 financial results on November 9, 2021, after market close, followed by a conference call at 1:30 p.m. PT. The company is known for its innovative Proteograph™ Product Suite, designed for advanced proteomic analysis. This system utilizes proprietary nanoparticles and automation to facilitate in-depth research quickly and efficiently. The results and details will be accessible via Seer’s investor website.
Seer, a life sciences company specializing in proteomics, announced its participation in the Morgan Stanley Global Healthcare Conference. The virtual fireside chat is scheduled for September 9 at 9:30 a.m. Pacific Time. A live webcast will be accessible on Seer's investor website, with an archived replay available post-conference. Seer’s Proteograph Product Suite provides deep proteomic analysis using innovative technology to enhance research capabilities across various labs. This product is intended for research use only and not for diagnostic procedures.
Seer, Inc. (Nasdaq: SEER) reported significant growth in Q2 2021, with revenues surging to $1.3 million from $71,000 in Q2 2020, driven by sales of the Proteograph Product Suite. The company booked initial revenue and expanded its customer base, including its first international client, while entering the Chinese market through a partnership with Enlight Medical. However, operating expenses increased to $17.4 million, resulting in a net loss of $16.6 million. As of June 30, 2021, Seer held approximately $518 million in cash and investments.
Seer (NASDAQ: SEER) partnered with Enlight Medical to distribute its Proteograph Product Suite in China. This collaboration aims to enhance access to Seer’s innovative proteomics platform in one of the world's fastest-growing life sciences markets. The partnership enables Enlight Medical to leverage its industry experience and connections to facilitate sales and marketing. Seer’s Proteograph technology targets biomarker discovery, essential for research in oncology and other diseases. This agreement is expected to accelerate Seer’s commercial presence in China, meeting the rising healthcare demands in the region.
Seer, Inc. (Nasdaq: SEER) will announce its Q2 2021 financial results on August 12, 2021, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET. Live audio will be available on Seer’s investor website, with replays following the event. The company is known for its Proteograph Product Suite, designed for deep proteomic analysis, revolutionizing research with easy-to-use tools for labs. Seer emphasizes that the Proteograph is for research only and not for diagnostics.
Seer, Inc. (Nasdaq: SEER) reported Q1 2021 financial results, revealing a revenue decrease to $62,000 from $177,000 in Q1 2020, attributed to diminished activity linked to an NIH grant. The company's operating expenses surged to $16.6 million, a significant rise from $6.0 million the previous year, mainly due to increased employee costs and product development expenses. The net loss widened to $16.4 million compared to $5.5 million in the prior year. The company maintained a robust cash position of approximately $531 million as of March 31, 2021.
Seer, a life sciences company known for its innovative proteomics platform, announced participation in the BofA Securities 2021 Healthcare Conference. The event will take place virtually on May 13 at 10:15 a.m. PT and will feature a fireside chat with management. Investors can access the live webcast through the Investor section of Seer’s website, with an archived replay available afterward. Seer's Proteograph Product Suite offers advanced, unbiased proteomic analysis, designed for use in various laboratories.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
